lifestyle.xbode.org

Author: Innovent Biologics,Inc

Mazdutide 9mg Supplementary Application Accepted for Review by China’s NMPA, Potentially Offering a Novel Drug Option for Moderate-to-Severe Obese Population

November 25, 2025
Innovent Biologics Enters Hang Seng Index and Two Other Major Indices; Global Capital Markets Recognize Leading Innovator’s Value

November 24, 2025
Mazdutide 9 mg Achieves Up to 20.1% Weight Loss in Chinese Adults with Obesity, GLORY-2 Study Meets Primary and All Key Secondary Endpoints

November 22, 2025
Multiple Research Results from Innovent’s General Biomedicine Pipeline Showcased at 2025 ACR Annual Meeting

November 7, 2025